Contact Us
  • Choose License Type

Global Proton Pump Inhibitors Market, by Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, and Others), by Disease Indication (Ulcers, Gastroesophageal Reflux Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key players are focusing on product approvals and launches to strengthen their position in the global proton pump inhibitors market. For instance, in 2016, Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, announced the launch of YOSPRALA, a prescription medicine with fixed dose of aspirin and omeprazole, for individuals who require secondary prevention of aspirin in cardiovascular diseases and also have higher risk of developing aspirin associated gastric ulcers.

Moreover, the increasing prevalence of gastroesophageal reflux disease in individuals older than 30 years in males and females is expected to drive the global proton pump inhibitors market growth. The US National Library of Medicine Report published in July 2020 has stated that gastroesophageal reflux disease is the most common gastro-intestinal disease in the U.S., with an estimated prevalence rate of 18.1 to 27%.

Global Proton Pump Inhibitors Market – Impact of Coronavirus (COVID-19)

  • The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the global proton pump inhibitor market growth.
  • Moreover, in July 2020, the American Journal of Gastroenterology conducted the surveillance study on COVID-19 infection risk in patients using proton pump inhibitors for hyperacidity, GERD and heartburn. The study examined online surveys of more than 53,000 Americans with a history of gastroesophageal reflux disease (GERD), and individuals who use PPIs and found that more than 6% of survey respondents were admitted to hospitals due to COVID-19 infection.

Browse 33 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on Global Proton Pump Inhibitors Market, by Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, and Others), by Disease Indication (Ulcers, Gastroesophageal Reflux Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the Global Proton Pump Inhibitors Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/proton-pump-inhibitors-market-4225

The market is expected to witness significant growth during the forecast period as key players are focusing on product approvals and launches of proton pump inhibitors for treatment of various gastro-intestinal diseases such as gastroesophageal reflux disease, heartburn and hyperacidity. For instance, in 2018, Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, launched omeprazole delayed released tablet with 20 mg strength and over-the-counter category proton pump inhibitor for the treatment of heartburn in the U.S.

Key Takeaways of the Global Proton Pump Inhibitors Market:

  • The global proton pump inhibitors market is expected to exhibit a CAGR of 4.30% during the forecast period owing to product approvals and launches and increasing prevalence of gastro-intestinal diseases such as GERD and duodenal ulcers.
  • Among type, the Omeprazole segment is expected to hold a highest market share in 2020, owing to a significant increase in launch of generics of omeprazole by local and generic manufacturing pharmaceutical companies.
  • Among disease indication, gastroesophageal reflux disease segment held a higher market share in 2020 owing to rising prevalence of gastroesophageal reflux disease in children and adults globally.
  • Companies operating in the global proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner